Curative efficacy analysis of allo-HSCT using conditioning regimen of FLAG combined with modified BUCY for refractory and relapsed patients with hematologic malignancies.
- Author:
Zhi-Hong WANG
1
;
Xiao-Xiong WU
;
Zhou-Yang LIU
;
Jian MA
;
Yong-Bin CAO
;
Li-Xin XU
;
Ya-Mei WU
;
Bei LIU
;
Bei YAN
;
Wan-Ming DA
Author Information
1. Department of Hematology, Clinical Division 304, Chinese PLA General Hospital, Beijing 100048, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Female;
Hematologic Neoplasms;
surgery;
therapy;
Hematopoietic Stem Cell Transplantation;
methods;
Humans;
Male;
Middle Aged;
Transplantation Conditioning;
methods;
Young Adult
- From:
Journal of Experimental Hematology
2011;19(1):158-162
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the curative efficacy of allogenetic hemopoietic stem cell transplantation (allo-HSCT) using FLAG and modified BUCY conditioning regimen for patients with refractory and relapse or high risk hematologic malignancies. The therapeutic effect of allo-HSCT with FLAG and modified BUCY conditioning regimen on 10 patients with hematologic malignancies was analyzed. 10 patients included 2 cases of relapse (1 early relapse, 1 progression) and 7 cases of refractory (2 CR(2), 1 CR(3) and 2 PR and 1 NR) and 1 CR(1) with high risk. Among 10 cases 8 cases was diagnosed as AML, 1 case as pro-T lymphoblast lymphoma/leukemia and 1 case as spleen marginal zone lymphoma. The results showed that implantation of all the patients was successful. The relapse-free median survival time of 8 cases was 164 days (57 - 442 days) and survived up to now, 2 cases died (1 case died of pulmonary infection, 1 case died of fungus pulmonitis). In conclusion, the curative efficacy of allo-HSCT using FLAG and modified BUCY conditioning regimen for patients with refractory and relapsed hematologic malignancies is satisfactory.
